Corticosteroid

Global Irritable Bowel Disease (IBD) Market Analysis Report 2024: Increasing Prevalence of Crohn's Disease, and Ulcerative Colitis Driving the $21 Billion Market - Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 12, 2024
General Health, Pharmaceutical, Health, Corticosteroid, TNF, Injection (medicine), Growth, Prevalence, Porter's five forces analysis, Incidence, SWOT, Disease, Research, IBD, Market, Medicine, Crohn's disease, Route of administration, Ulcerative colitis, USD, Administration, JAK, Irritable bowel syndrome, Pharmaceutical industry

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.

Key Points: 
  • The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.
  • The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
    The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).

InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial

Retrieved on: 
星期二, 十一月 21, 2023
Stem Cells, Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Science, Clinical Trials, DRS, Prevalence, Literature, Data, Cell, Patient, Answer, Knee pain, Cartilage, RT, Corticosteroid, Injection, Nature Medicine, Pharmaceutical industry, Osteoarthritis

InGeneron, Inc., a clinical stage biotechnology company, announces a critical in-depth analysis of the results from a 480-patient Phase III knee osteoarthritis (OA) trial that was recently published in the Journal Nature Medicine on November 2nd, 2023.

Key Points: 
  • InGeneron, Inc., a clinical stage biotechnology company, announces a critical in-depth analysis of the results from a 480-patient Phase III knee osteoarthritis (OA) trial that was recently published in the Journal Nature Medicine on November 2nd, 2023.
  • Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
  • A critical in-depth analysis titled “ Management of Knee Pain in Osteoarthritis with Orthobiologics and Corticosteroid Injection: More Questions than Answers ” was published on November 16th by Drs.
  • Specifically, the in-depth analysis raises the question whether a more differentiated analysis of patient sub-populations might have found a different result.

Insights on the $26.1 Billion Psoriasis Treatment Global Market to 2027 - Featuring AbbVie, Amgen, Novartis International and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
星期三, 一月 25, 2023
Health, Pharmaceutical, Growth, Psoriasis, Corticosteroid, TNF, Pharmaceutical industry, Pet industry, Video game

The global market for Psoriasis Treatment estimated at US$16.9 Billion in the year 2020, is projected to reach a revised size of US$26.1 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027.

Key Points: 
  • The global market for Psoriasis Treatment estimated at US$16.9 Billion in the year 2020, is projected to reach a revised size of US$26.1 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027.
  • Interleukin Inhibitors, one of the segments analyzed in the report, is projected to record a 6.1% CAGR and reach US$9.6 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $4.6 Billion, While China is Forecast to Grow at 11% CAGR
    The Psoriasis Treatment market in the U.S. is estimated at US$4.6 Billion in the year 2020.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.5 Billion by the year 2027.

Global Vasculitis Treatment Strategic Business Report 2022: 23 Players Featured Including AB Science, Astellas Pharma, AstraZeneca and Baxter International - ResearchAndMarkets.com

Retrieved on: 
星期三, 一月 25, 2023
Health, Pharmaceutical, Growth, Vasculitis, Corticosteroid, Pet industry

The "Vasculitis Treatment: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vasculitis Treatment: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • Biologics, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$301.1 Million by the end of the analysis period.
  • Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 3.2% CAGR for the next 7-year period.
  • In the global Immunosuppressants segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment.

Atopic Dermatitis Global Market Report 2022: Lack of Therapeutic Options for Chronic Hand Eczema Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
星期二, 十二月 20, 2022
Health, Pharmaceutical, Table, Administration, US, Atopic dermatitis, Gerber Products Company, Injection (medicine), Route of administration, AD, Prevalence, Plasma protein binding, Corticosteroid, Oil, Marketing, Bank, Risk management

The Global Atopic Dermatitis market report provides an executive-level overview of the atopic dermatits market worldwide today, with detailed forecasts of key indicators up to 2027.

Key Points: 
  • The Global Atopic Dermatitis market report provides an executive-level overview of the atopic dermatits market worldwide today, with detailed forecasts of key indicators up to 2027.
  • Atopic Dermatitis market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • Atopic Dermatitis market outlook: analysis as well as forecasts of revenue opportunities from the route of administrtaion segment.
  • This market intelligence report offers a thorough, forward-looking analysis of the global Atopic Dermatitis market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.

Regenerative Medicine in Pharma Market to Grow by 11.1% Annually Through 2027 - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 19, 2022
Health, Pharmaceutical, Astellas Institute for Regenerative Medicine, Table, Administration, US, Gerber Products Company, Injection (medicine), Route of administration, Regenerative medicine, Prevalence, Plasma protein binding, Conditional sentence, Corticosteroid, Cancer, Pharmaceutical industry, Fine chemical, Pharma

The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027.

Key Points: 
  • The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027.
  • The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
  • Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.

Global Non-Infectious Macular Edema Treatment Strategic Business Report 2022: 46 Companies Featured Including AbbVie, Alimera Sciences, Allergan and Amgen - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 12, 2022
Pharmaceutical, Health, Optical, Corticosteroid, Growth, Pet, Fossil fuel

The "Non-Infectious Macular Edema Treatment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Infectious Macular Edema Treatment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Anti-VEGF, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$12.5 Billion by the end of the analysis period.
  • Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 6.8% CAGR for the next 7-year period.
  • In the global Immunosuppressants segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment.

Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class, Route of Administration, and Segment Forecast, 2022-2027

Retrieved on: 
星期五, 十二月 9, 2022
Regenerative medicine, Gerber Products Company, Conditional sentence, Astellas Institute for Regenerative Medicine, Injection (medicine), Prevalence, Cancer, Plasma protein binding, US, Route of administration, Administration, Table, Corticosteroid, Pharmaceutical industry, Fine chemical, Pharma

The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.

Key Points: 
  • The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
  • - Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
    - Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
  • - Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • - Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.

Global Cancer Cachexia Market Trajectory & Analytics Report 2022: Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
星期三, 五月 11, 2022
Pharmaceutical, Health, Oncology, Cachexia, Corticosteroid, Combination, CAGR, Growth, Period, Pet

The "Cancer Cachexia - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Cachexia - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Progestogens, one of the segments analyzed in the report, is projected to grow at a 4.8% CAGR to reach US$1.2 Billion by the end of the analysis period.
  • This segment currently accounts for a 24.7% share of the global Cancer Cachexia market.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$211.8 Million by the year 2027.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential f

Retrieved on: 
星期五, 三月 18, 2022
Therapy, Fast Track, PALO, Leg, Disability, Hematoma, Sciatica, Paraplegia, Pain, Injection, Oswestry Disability Index, Quality of life, Safety, Corticosteroid, Radicular pain, Kaplan–Meier estimator, GLOBE, SEM, FDA, Pivotal trial, Patient, Low back pain, Infection, Birth control, Pharmaceutical industry, Radiculopathy

The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period.

Key Points: 
  • The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period.
  • PALO ALTO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced highly significant positive final results from its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R.
  • The trial enrolled 401 low back pain subjects with unilateral intervertebral disc herniation in lumbar spine resulting in radicular pain symptoms of moderate to severe leg pain.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.